{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Singh AK"],"funding":["GlaxoSmithKline","NIDDK NIH HHS","NIDDK"],"pagination":["1890-1897"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10387380"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["38(8)"],"pubmed_abstract":["Background
The prespecified on-treatment analysis of ASCEND-ND (NCT02876835) raised concerns about a higher relative risk of cancer-related adverse events (AEs) with daprodustat vs darbepoetin in patients with anaemia of CKD. This concern was not observed in dialysis patients in ASCEND-D (NCT02879305).Methods
ASCEND-ND randomized 3872 patients to daprodustat or darbepoetin. ASCEND-D randomized 2964 patients to daprodustat or conventional erythropoiesis-stimulating agents (ESAs). In both studies ESA comparators used different dosing intervals (3/week, 1/week, every 2 or every 4 weeks). The prespecified on-treatment approach examined relative risks for cancer AEs up to the last dose date + 1 day. In these analyses, owing to different dosing intervals between arms, Cox models "],"journal":["Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"],"pubmed_title":["Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials."],"pmcid":["PMC10387380"],"funding_grant_id":["R01DK129749","R03DK122240","R01 DK129749","R03 DK122240"],"pubmed_authors":["Meadowcroft A","Carroll K","McMurray JJV","Wiecek A","Perkovic V","DiMino T","Atkins MB","Claggett BL","Cobitz AR","Wanner C","Singh AK","Wittes J","McCausland FR","Snapinn S","Blackorby A","Solomon SD","Barker T","Mallett S"],"additional_accession":[]},"is_claimable":false,"name":"Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials.","description":"Background
The prespecified on-treatment analysis of ASCEND-ND (NCT02876835) raised concerns about a higher relative risk of cancer-related adverse events (AEs) with daprodustat vs darbepoetin in patients with anaemia of CKD. This concern was not observed in dialysis patients in ASCEND-D (NCT02879305).Methods
ASCEND-ND randomized 3872 patients to daprodustat or darbepoetin. ASCEND-D randomized 2964 patients to daprodustat or conventional erythropoiesis-stimulating agents (ESAs). In both studies ESA comparators used different dosing intervals (3/week, 1/week, every 2 or every 4 weeks). The prespecified on-treatment approach examined relative risks for cancer AEs up to the last dose date + 1 day. In these analyses, owing to different dosing intervals between arms, Cox models ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2026-05-28T08:46:29.795Z","creation":"2025-04-04T19:01:43.372Z"},"accession":"S-EPMC10387380","cross_references":{"pubmed":["36565721"],"doi":["10.1093/ndt/gfac342"]}}